Sonnet BioTherapeutics Holdings, Inc. (SONN) Intrinsic Value

DCF-based fair value calculation with Bear, Base, and Bull scenarios

Popular:

Sonnet BioTherapeutics Holdings, Inc. (SONN)

View Full Profile →

Intrinsic Value

DCF Not Suitable for SONN

Market cap ($0.01B) below $1B threshold — DCF not reliable for small-cap/micro-cap stocks.

Alternative Approach:

Use relative valuation (P/E, P/S) vs. peer group.

Frequently Asked Questions

Is SONN stock undervalued or overvalued?

Insufficient data to compute DCF valuation for SONN. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.

What is SONN's intrinsic value?

Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.

How is SONN's fair value calculated?

Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For SONN, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.